These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8120520)

  • 21. [Attempt in treating benign insulinoma by delayed somatostatin. 2 cases].
    Picq R; Vialettes B; de la Tour d'Auvergne M; Joliot AY; Vague P
    Presse Med; 1988 Nov; 17(39):2087. PubMed ID: 2849769
    [No Abstract]   [Full Text] [Related]  

  • 22. [Malignant insulinoma: lack of response to the somatostatin analog SMS 201-955].
    Ligorria C; Montaña E; Virgili N
    Med Clin (Barc); 1989 Nov; 93(17):676. PubMed ID: 2559266
    [No Abstract]   [Full Text] [Related]  

  • 23. Somatostatin analog inhibits the growth of insulinoma cells by p27-mediated G1 cell cycle arrest.
    Aoki T; Motoi F; Sakata N; Naitoh T; Katayose Y; Egawa S; Miyazaki J; Unno M
    Pancreas; 2014 Jul; 43(5):720-9. PubMed ID: 24694834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
    Blanchin M; James-Deidier A; Chaumet-Riffaud PD; Chayvialle JA
    Presse Med; 1992 Apr; 21(15):697-702. PubMed ID: 1376476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug?
    Stehouwer CD; Lems WF; Fischer HR; Hackeng WH
    Neth J Med; 1989 Aug; 35(1-2):86-94. PubMed ID: 2550827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin analogues in the management of benign insulinomas.
    Laron Z
    Isr J Med Sci; 1990 Jan; 26(1):1-2. PubMed ID: 2155883
    [No Abstract]   [Full Text] [Related]  

  • 27. Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas.
    Nakamura A; Mitsuhashi T; Takano Y; Miyoshi H; Kameda H; Nomoto H; Nagai S; Hatanaka Y; Shimizu C; Terauchi Y; Atsumi T
    Endocr J; 2016; 63(2):135-42. PubMed ID: 26567922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of malignant insulinoma: successful control of glycemic fluctuation by replacing octreotide injections with octreotide LAR injections.
    Okamoto M; Kishimoto M; Takahashi Y; Osame K; Noto H; Yamamoto-Honda R; Kajio H; Tokuhara M; Edamoto Y; Endo H; Igari T; Kubota K; Noda M
    Endocr J; 2013; 60(8):951-7. PubMed ID: 23665775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
    Arnold R; Neuhaus C; Trautmann ME
    Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
    [No Abstract]   [Full Text] [Related]  

  • 30. Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours.
    Lamberts SW; Pieters GF; Metselaar HJ; Ong GL; Tan HS; Reubi JC
    Acta Endocrinol (Copenh); 1988 Dec; 119(4):561-6. PubMed ID: 2849276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues?
    Gilliaux Q; Bertrand C; Hanon F; Donckier JE
    Acta Chir Belg; 2022 Apr; 122(2):136-139. PubMed ID: 32375590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pasireotide for malignant insulinoma.
    Tirosh A; Stemmer SM; Solomonov E; Elnekave E; Saeger W; Ravkin Y; Nir K; Talmor Y; Shimon I
    Hormones (Athens); 2016 Apr; 15(2):271-276. PubMed ID: 26732164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.
    Healy ML; Dawson SJ; Murray RM; Zalcberg J; Jefford M
    Intern Med J; 2007 Jun; 37(6):406-9. PubMed ID: 17535385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of insulinoma with the somatostatin analog SMS 201-995].
    Gilsanz Peral A; Gómez Balaguer M; Costa Talens P
    Med Clin (Barc); 1988 Apr; 90(15):634-5. PubMed ID: 2899658
    [No Abstract]   [Full Text] [Related]  

  • 35. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verapamil, a calcium channel blocker drug.
    Kelestimur F
    Acta Endocrinol (Copenh); 1993 Jan; 128(1):99. PubMed ID: 8447201
    [No Abstract]   [Full Text] [Related]  

  • 37. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism.
    Vezzosi D; Bennet A; Courbon F; Caron P
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):904-11. PubMed ID: 18031316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Insulinoma effectively controlled with low dose of octreotide acetate].
    Fukuoka K; Matsushita M; Murase T; Yamamori I
    Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2786-8. PubMed ID: 18203414
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical Management of Malignant Insulinoma: a single Institution's experience over three decades.
    Yu J; Ping F; Zhang H; Li W; Yuan T; Fu Y; Feng K; Xia W; Xu L; Li Y
    BMC Endocr Disord; 2018 Dec; 18(1):92. PubMed ID: 30522468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).
    Wynick D; Anderson JV; Williams SJ; Bloom SR
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):385-8. PubMed ID: 2557179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.